Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progression.

[1]  M. Kamel,et al.  The Anti-Obesity and Anti-Steatotic Effects of Chrysin in a Rat Model of Obesity Mediated through Modulating the Hepatic AMPK/mTOR/lipogenesis Pathways , 2023, Molecules.

[2]  Z. Fišar,et al.  Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study , 2022, International journal of molecular sciences.

[3]  F. Gao,et al.  A mixed blessing for liver transplantation patients - Rapamycin. , 2022, Hepatobiliary & pancreatic diseases international : HBPD INT.

[4]  Z. Su,et al.  mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.

[5]  S. Simon,et al.  mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling , 2022, Communications Biology.

[6]  J. Dillon,et al.  Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD , 2022, Journal of clinical and translational hepatology.

[7]  D. Goulis,et al.  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease , 2022, Current Obesity Reports.

[8]  Kahealani Uehara,et al.  Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1 , 2022, Science.

[9]  R. Andrade,et al.  Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation , 2022, Scientific reports.

[10]  Jaimarie Sostre-Colón,et al.  Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis , 2022, Cellular and molecular gastroenterology and hepatology.

[11]  H. Farghali,et al.  mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. , 2022, European journal of pharmacology.

[12]  P. Muriel,et al.  Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma. , 2021, Biochemical pharmacology.

[13]  M. Kaeberlein,et al.  Evidence that C/EBP-β LAP Increases Fat Metabolism and Protects Against Diet-Induced Obesity in Response to mTOR Inhibition , 2021, Frontiers in Aging.

[14]  J. Cui,et al.  Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy , 2021, Autophagy.

[15]  M. Honda,et al.  Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease , 2021, Medicine.

[16]  Chris S. Pridgeon,et al.  CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload , 2021, International journal of molecular sciences.

[17]  E. Harris,et al.  Pathophysiological Communication between Hepatocytes and Non-Parenchymal Cells in Liver Injury from NAFLD to Liver Fibrosis. , 2021, Advanced drug delivery reviews.

[18]  M. Elkalaf,et al.  Western Diet Decreases the Liver Mitochondrial Oxidative Flux of Succinate: Insight from a Murine NAFLD Model , 2021, International journal of molecular sciences.

[19]  P. Pávek,et al.  Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis , 2021, International journal of molecular sciences.

[20]  K. Zieniewicz,et al.  Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship , 2021, European journal of clinical investigation.

[21]  Ming O. Li,et al.  Sestrin Proteins Protect Against Lipotoxicity-Induced Oxidative Stress in the Liver via Suppression of C-Jun N-Terminal Kinases , 2021, Cellular and molecular gastroenterology and hepatology.

[22]  Yajing Guo,et al.  A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH. , 2021, Life sciences.

[23]  Geng-Ruei Chang,et al.  Chronic everolimus treatment of high‐fat diet mice leads to a reduction in obesity but impaired glucose tolerance , 2021, Pharmacology research & perspectives.

[24]  V. Athwal,et al.  Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications , 2021, Current Diabetes Reports.

[25]  Doyoung Kwon,et al.  Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models , 2020, Biology.

[26]  Jun Wang,et al.  Inositol requiring enzyme 1 alpha (IRE1a) links palmitate-induced mTOR activation and lipotoxicity in Hepatocytes. , 2020, American journal of physiology. Cell physiology.

[27]  H. Zischka,et al.  Western Diet Causes Obesity-Induced Nonalcoholic Fatty Liver Disease Development by Differentially Compromising the Autophagic Response , 2020, Antioxidants.

[28]  Jing Yang,et al.  Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway , 2020, Peptides.

[29]  I. Raška,et al.  Alternative isoforms of KDM2A and KDM2B lysine demethylases negatively regulate canonical Wnt signaling , 2020, bioRxiv.

[30]  S. Softic,et al.  Evolving Role for Pharmacotherapy in NAFLD/NASH , 2020, Clinical and translational science.

[31]  Krisy-Ann Thornby,et al.  A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease , 2020, The Annals of pharmacotherapy.

[32]  Yoon-Young Choi,et al.  Co-administration of everolimus and N-acetylcysteine attenuates hepatic stellate cell activation and hepatic fibrosis. , 2020, American journal of translational research.

[33]  R. Zhao,et al.  Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease , 2020, Frontiers in Chemistry.

[34]  E. L. Miller.  Nutrition Management Strategies for Nonalcoholic Fatty Liver Disease: Treatment and Prevention , 2020, Clinical liver disease.

[35]  Jinglei Li,et al.  High fat diet induced obesity model using four strains of mice: Kunming, C57BL/6, BALB/c and ICR , 2020, Experimental animals.

[36]  Zhe Pan,et al.  Lipin1 mediates cognitive impairment in fld mice via PKD-ERK pathway. , 2020, Biochemical and biophysical research communications.

[37]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[38]  P. Staňková,et al.  Adaptation of Mitochondrial Substrate Flux in a Mouse Model of Nonalcoholic Fatty Liver Disease , 2020, International journal of molecular sciences.

[39]  V. Karamyan,et al.  Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? , 2019, Pharmaceutical Research.

[40]  Lijun Xu,et al.  Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells , 2019, BMC Complementary and Alternative Medicine.

[41]  Umesh Panwar,et al.  An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer , 2019, Asian Pacific journal of cancer prevention : APJCP.

[42]  N. Zahr,et al.  Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation , 2019, Drug Safety.

[43]  H. Wanibuchi,et al.  mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans , 2018, Cancers.

[44]  Chunjiong Wang,et al.  Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis , 2018, Cellular and molecular gastroenterology and hepatology.

[45]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[46]  Jingping Liu,et al.  Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non‐alcoholic steatohepatitis , 2018, Life sciences.

[47]  G. Ren,et al.  SIRT1 upregulation protects against liver injury induced by a HFD through inhibiting CD36 and the NF-κB pathway in mouse kupffer cells , 2018, Molecular medicine reports.

[48]  M. Hall,et al.  mTORC2 Promotes Tumorigenesis via Lipid Synthesis. , 2017, Cancer cell.

[49]  O. Sobotka,et al.  Acetaminophen toxicity in rat and mouse hepatocytes in vitro , 2017, Drug and chemical toxicology.

[50]  Yufeng Xie,et al.  mTOR Inhibition Rejuvenates the Aging Gingival Fibroblasts through Alleviating Oxidative Stress , 2017, Oxidative medicine and cellular longevity.

[51]  D. Wink,et al.  Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers. , 2017, Antioxidants & redox signaling.

[52]  Gurdarshan Singh,et al.  Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis , 2017, Oncotarget.

[53]  Xianhui Li,et al.  Rapamycin attenuates palmitate-induced lipid aggregation by up-regulating sirt-1 signaling in AML12 hepatocytes. , 2016, Die Pharmazie.

[54]  S. Landas,et al.  Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus‐Prone Mice , 2016, Arthritis & rheumatology.

[55]  R. Pamplona,et al.  Rapamycin reverses age-related increases in mitochondrial ROS production at complex I, oxidative stress, accumulation of mtDNA fragments inside nuclear DNA, and lipofuscin level, and increases autophagy, in the liver of middle-aged mice , 2016, Experimental Gerontology.

[56]  C. Proud,et al.  mTOR inhibitors in cancer therapy , 2016, F1000Research.

[57]  Chunchun Han,et al.  Effects of inhibiting PI3K-Akt-mTOR pathway on lipid metabolism homeostasis in goose primary hepatocytes. , 2016, Animal : an international journal of animal bioscience.

[58]  P. LoRusso,et al.  A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies , 2016, British Journal of Cancer.

[59]  J. Fernandez-Checa,et al.  Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis , 2015, Oncotarget.

[60]  Huang Haijun,et al.  Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo. , 2015, Biochemical and biophysical research communications.

[61]  Alexandre Caron,et al.  The Roles of mTOR Complexes in Lipid Metabolism. , 2015, Annual review of nutrition.

[62]  K. Kodys,et al.  Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat–cholesterol–sugar diet model in mice , 2015, Journal of Translational Medicine.

[63]  Hehe Liu,et al.  The Regulation of Lipid Deposition by Insulin in Goose Liver Cells Is Mediated by the PI3K-AKT-mTOR Signaling Pathway , 2015, PloS one.

[64]  R. Kleemann,et al.  Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology , 2014, PloS one.

[65]  R. Matthews,et al.  Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition , 2014, Hepatology.

[66]  Dudley Lamming,et al.  Rapamycin-induced metabolic defects are reversible in both lean and obese mice , 2014, Aging.

[67]  M. Karin,et al.  Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. , 2014, Cell metabolism.

[68]  Houliang Deng,et al.  Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells. , 2014, Journal of ethnopharmacology.

[69]  Elizabeth Murphy,et al.  Pivotal Role of mTORC2 and Involvement of Ribosomal Protein S6 in Cardioprotective Signaling , 2014, Circulation research.

[70]  H. Uhlig,et al.  Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies , 2014, Pediatric Research.

[71]  D. Bonthron,et al.  High‐fat and high‐sucrose (western) diet induces steatohepatitis that is dependent on fructokinase , 2013, Hepatology.

[72]  Shi-Yong Sun,et al.  mTOR kinase inhibitors as potential cancer therapeutic drugs. , 2013, Cancer letters.

[73]  D. Schuppan,et al.  Non‐alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches , 2013, Journal of gastroenterology and hepatology.

[74]  S. Ki,et al.  Role of the Nrf2-ARE Pathway in Liver Diseases , 2013, Oxidative medicine and cellular longevity.

[75]  H. Zhang,et al.  A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models , 2013, PloS one.

[76]  F. Booth,et al.  PGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[77]  E. Raymond,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma , 2012, British Journal of Cancer.

[78]  F. Rieder,et al.  Cellular and molecular mechanisms of intestinal fibrosis. , 2012, World journal of gastroenterology.

[79]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[80]  M. Hall,et al.  Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. , 2012, Cell metabolism.

[81]  P. Sorger,et al.  Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics* , 2012, The Journal of Biological Chemistry.

[82]  C. Deng,et al.  Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. , 2011, The Journal of clinical investigation.

[83]  K. Shokat,et al.  The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile , 2011, Proceedings of the National Academy of Sciences.

[84]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[85]  D. Feinstein,et al.  The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes , 2011, Journal of Neuroinflammation.

[86]  Giuseppe Lippi,et al.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[87]  Yugang Wang,et al.  Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease. , 2010, Molecular medicine reports.

[88]  C. Hellerbrand,et al.  Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. , 2010, Journal of hepatology.

[89]  H. Farghali,et al.  Resveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1. , 2009, Nitric oxide : biology and chemistry.

[90]  Lisa L. Smith,et al.  The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. , 2009, Bioorganic & medicinal chemistry letters.

[91]  Chin-Lee Wu,et al.  Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway , 2009, PloS one.

[92]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[93]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[94]  C. Chresta,et al.  319 POSTER Pharmacodynamics and anti-tumour activity of KU-0063794, a potent and specific inhibitor of mTOR kinase , 2008 .

[95]  J. Rovira,et al.  Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[96]  F. Bellanti,et al.  Alterations of hepatic ATP homeostasis and respiratory chain during development of non‐alcoholic steatohepatitis in a rodent model , 2008, European journal of clinical investigation.

[97]  H. Farghali,et al.  Modulation of Spontaneous and Lipopolysaccharide-Induced Nitric Oxide Production and Apoptosis by D-Galactosamine in Rat Hepatocyte Culture: The Significance of Combinations of Different Methods , 2008, Toxicology mechanisms and methods.

[98]  G. Perdomo,et al.  The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. , 2007, Metabolism: clinical and experimental.

[99]  J. Reichen,et al.  Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. , 2006, Journal of hepatology.

[100]  G. Schonfeld,et al.  Hepatic triglyceride contents are genetically determined in mice: results of a strain survey. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[101]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[102]  Insuk Sohn,et al.  Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. , 2004, Gene.

[103]  Y. Eto,et al.  Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. , 2003, Biochemical and biophysical research communications.

[104]  R. Farzaneh-Far,et al.  Nitric oxide and the liver. , 2001, Liver.

[105]  M. Zern,et al.  Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. , 1999, Gastroenterology.

[106]  T. Billiar,et al.  Inducible nitric oxide synthase in the liver: regulation and function. , 1998, Biochemistry. Biokhimiia.

[107]  M. Toborek,et al.  Susceptibility to hepatic oxidative stress in rabbits fed different animal and plant fats. , 1996, Journal of the American College of Nutrition.

[108]  M. Berry,et al.  Isolated Hepatocytes: Preparation, Properties and Applications , 1991 .

[109]  W. Cai,et al.  Autophagy May Protect Against Parenteral Nutrition-Associated Liver Disease by Suppressing Endoplasmic Reticulum Stress. , 2019, JPEN. Journal of parenteral and enteral nutrition.

[110]  H. Farghali,et al.  D-galactosamine/lipopolysaccharide-induced hepatotoxicity downregulates sirtuin 1 in rat liver: role of sirtuin 1 modulation in hepatoprotection. , 2014, Physiological research.

[111]  C. Palmeira,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free Radical Biology & Medicine.

[112]  Geng-Ruei Chang,et al.  Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. , 2009, Journal of pharmacological sciences.

[113]  L. Chan,et al.  The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. , 2000, Metabolism: clinical and experimental.